AC Immune SA (NASDAQ:ACIU) Short Interest Up 23.5% in October

AC Immune SA (NASDAQ:ACIUGet Free Report) was the recipient of a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 984,500 shares, a growth of 23.5% from the October 15th total of 796,900 shares. Based on an average daily volume of 92,100 shares, the short-interest ratio is presently 10.7 days. Currently, 1.6% of the company’s stock are sold short.

Institutional Investors Weigh In On AC Immune

Several institutional investors have recently bought and sold shares of ACIU. BNP Paribas Financial Markets lifted its holdings in shares of AC Immune by 315.6% during the 1st quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company’s stock valued at $33,000 after purchasing an additional 8,423 shares during the last quarter. Lazard Asset Management LLC purchased a new stake in AC Immune in the first quarter valued at about $30,000. Redmile Group LLC boosted its holdings in AC Immune by 0.4% in the first quarter. Redmile Group LLC now owns 2,007,031 shares of the company’s stock worth $5,941,000 after acquiring an additional 7,031 shares in the last quarter. Silverberg Bernstein Capital Management LLC purchased a new stake in shares of AC Immune during the second quarter worth about $40,000. Finally, Assenagon Asset Management S.A. increased its holdings in shares of AC Immune by 294.7% during the second quarter. Assenagon Asset Management S.A. now owns 439,730 shares of the company’s stock valued at $1,755,000 after acquiring an additional 328,312 shares in the last quarter. 51.36% of the stock is currently owned by institutional investors and hedge funds.

AC Immune Stock Performance

NASDAQ:ACIU opened at $3.19 on Friday. The company’s 50-day simple moving average is $3.28 and its 200-day simple moving average is $3.48. AC Immune has a fifty-two week low of $2.25 and a fifty-two week high of $5.14. The stock has a market capitalization of $315.62 million, a P/E ratio of -6.93 and a beta of 1.28.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on ACIU shares. StockNews.com lowered shares of AC Immune from a “buy” rating to a “hold” rating in a report on Tuesday, October 1st. HC Wainwright reiterated a “buy” rating and issued a $16.00 price target on shares of AC Immune in a report on Friday.

Read Our Latest Stock Report on ACIU

AC Immune Company Profile

(Get Free Report)

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Further Reading

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.